Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX) Forms $25.13 Double Top; 6 Analysts Bullish Charles River Laboratories International, Inc. (CRL)

Among 16 analysts covering Charles River Laboratories (NYSE:CRL), 6 have Buy rating, 1 Sell and 9 Hold. Therefore 38% are positive. Charles River Laboratories had 41 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Market Perform” rating given on Monday, October 12 by Wells Fargo. On Thursday, November 2 the stock rating was maintained by RBC Capital Markets with “Hold”. Jefferies upgraded Charles River Laboratories International, Inc. (NYSE:CRL) on Monday, October 9 to “Buy” rating. KeyBanc Capital Markets maintained Charles River Laboratories International, Inc. (NYSE:CRL) on Thursday, October 12 with “Hold” rating. The firm earned “Buy” rating on Friday, November 10 by Bank of America. As per Monday, November 13, the company rating was maintained by Robert W. Baird. Citigroup maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating on Thursday, August 4. Citigroup has “Neutral” rating and $90 target. Credit Suisse maintained it with “Hold” rating and $112.0 target in Monday, October 16 report. Robert W. Baird maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating on Thursday, August 31. Robert W. Baird has “Buy” rating and $114.0 target. Credit Suisse initiated Charles River Laboratories International, Inc. (NYSE:CRL) rating on Tuesday, June 21. Credit Suisse has “Neutral” rating and $84 target. See Charles River Laboratories International, Inc. (NYSE:CRL) latest ratings:

22/01/2018 Broker: SunTrust Rating: Hold Downgrade
19/01/2018 Broker: Evercore Rating: In-Line New Target: $117 Initiates Coverage On
13/12/2017 Broker: Argus Research Rating: Buy New Target: $120 Initiates Coverage On
16/11/2017 Broker: SunTrust Rating: Buy New Target: $113.0 Maintain
13/11/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain
13/11/2017 Broker: Robert W. Baird Rating: Buy New Target: $117.0 Maintain
13/11/2017 Broker: Jefferies Rating: Buy Old Target: $135 New Target: $124 Maintain
10/11/2017 Broker: Bank of America Rating: Buy Old Target: $117 New Target: $115 Maintain
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $110.0 Maintain
16/10/2017 Broker: Credit Suisse Rating: Hold New Target: $112.0 Maintain

Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX) formed double top with $26.64 target or 6.00% above today’s $25.13 share price. Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX) has $ valuation. The stock decreased 1.30% or $0.33 during the last trading session, reaching $25.13. About 67,637 shares traded. Nuveen Nasdaq 100 Dynamic Overwrite Fund (NASDAQ:QQQX) has risen 24.35% since January 30, 2017 and is uptrending. It has outperformed by 7.65% the S&P500.

Investors sentiment decreased to 1.5 in 2017 Q3. Its down 0.19, from 1.69 in 2017Q2. It dived, as 5 investors sold Nuveen Nasdaq 100 Dynamic Overwrite Fund shares while 11 reduced holdings. 6 funds opened positions while 18 raised stakes. 4.92 million shares or 1.16% less from 4.98 million shares in 2017Q2 were reported. 3,591 are owned by Hanson Mcclain. Natl Planning reported 18,219 shares. Royal State Bank Of Canada holds 0.01% in Nuveen Nasdaq 100 Dynamic Overwrite Fund (NASDAQ:QQQX) or 596,601 shares. Morgan Stanley holds 0.01% or 1.28M shares. American National Bank reported 0.07% stake. Pnc Finance has 0% invested in Nuveen Nasdaq 100 Dynamic Overwrite Fund (NASDAQ:QQQX). Georgia-based Advisory Networks Ltd Liability Company has invested 0% in Nuveen Nasdaq 100 Dynamic Overwrite Fund (NASDAQ:QQQX). 33,759 were reported by Oppenheimer And. Thomas J Herzfeld Advsrs Inc owns 1,502 shares. Invesco Limited has 309,606 shares. Private Advisor Lc owns 23,866 shares. Blume Capital Management holds 0% of its portfolio in Nuveen Nasdaq 100 Dynamic Overwrite Fund (NASDAQ:QQQX) for 210 shares. Sei Co has invested 0% in Nuveen Nasdaq 100 Dynamic Overwrite Fund (NASDAQ:QQQX). Pennsylvania-based Janney Montgomery Scott Ltd Llc has invested 0.03% in Nuveen Nasdaq 100 Dynamic Overwrite Fund (NASDAQ:QQQX). 13,113 were accumulated by Creative Planning.

Investors sentiment increased to 1.46 in Q3 2017. Its up 0.09, from 1.37 in 2017Q2. It improved, as 18 investors sold Charles River Laboratories International, Inc. shares while 92 reduced holdings. 55 funds opened positions while 106 raised stakes. 44.95 million shares or 0.15% less from 45.02 million shares in 2017Q2 were reported. Bb&T Ltd Liability Co reported 0% stake. Clinton Grp Inc stated it has 0.06% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL). Wright Investors Service holds 0.28% in Charles River Laboratories International, Inc. (NYSE:CRL) or 7,191 shares. Bessemer Group reported 1,760 shares. Amica Retiree Med holds 1,634 shares or 0.14% of its portfolio. Inv House Limited Liability Company stated it has 92,245 shares or 1.3% of all its holdings. California-based Eqis Capital Mngmt has invested 0.03% in Charles River Laboratories International, Inc. (NYSE:CRL). Tygh Cap Mgmt, Oregon-based fund reported 36,107 shares. Renaissance Tech Limited Liability holds 1.34M shares. 8,447 were accumulated by Cardinal Capital Management. Leavell Investment Mngmt Incorporated holds 0.06% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL) for 4,800 shares. 14,830 were accumulated by Ngam L P. Commonwealth Of Pennsylvania Public School Empls Retrmt reported 6,943 shares. The Ohio-based Keybank National Association Oh has invested 0% in Charles River Laboratories International, Inc. (NYSE:CRL). Principal Fincl Group Inc reported 0.02% in Charles River Laboratories International, Inc. (NYSE:CRL).

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. The company has market cap of $5.06 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It has a 26.09 P/E ratio. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

The stock decreased 0.58% or $0.62 during the last trading session, reaching $106.85. About 101,334 shares traded. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 7.06% since January 30, 2017 and is uptrending. It has underperformed by 9.64% the S&P500.